Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director · PRESIDENT, CEO AND DIRECTOR | May 25, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SANGAMO THERAPEUTICS, INC
Report date May 25, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,895,043 |
Reported balance
After 2026-05-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-25 · Tax withholding · Disposed 12,613 · Balance 1,895,043 F1: Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2: Includes: 22,543 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 246,094 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2: Includes: 22,543 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 246,094 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2026 Filed May 27, 2026 23:30 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 12,613 | $0.17 | $2,198.45 |
DisclosureSEC source: 0001675687-26-000008 · form4-05272026_070501.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,895,043 F1 · shares: Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: 22,543 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 246,094 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:15 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 2,500,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001675687-26-000006 · form4-04032026_040401.xml · derivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 02:40 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 33,637 | $0.47 | $15,809.39 |
DisclosureSEC source: 0001675687-26-000004 · form4-02262026_090209.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,907,656 F3 · shares: Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F4 · balance_after: Includes: 60,113 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 281,250 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 02:40 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 5,291 | $0.47 | $2,500.00 |
DisclosureSEC source: 0001675687-26-000004 · form4-02262026_090209.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,941,293 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 9,456 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 102,950 | $0.40 | $41,025.58 |
DisclosureSEC source: 0001675687-26-000002 · form4-01262026_090123.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,946,584 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 147,050 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 14,747 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,488 | $0.42 | $3,119.50 |
DisclosureSEC source: 0001675687-25-000008 · form4-11262025_091118.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,049,534 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 7,259 shares resulting from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 14,747 shares will vest on February 24, 2026, (b) 250,000 shares subject to Reporting Person's January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026, (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 21:00 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 126,950 | $0.66 | $83,787.00 |
DisclosureSEC source: 0001675687-25-000006 · form4-10242025_051007.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,057,022 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 123,050 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 250,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 29,494 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 24, 2025 Filed Aug 27, 2025 00:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,488 | $0.59 | $4,390.21 |
DisclosureSEC source: 0001415889-25-023081 · form4-08272025_120812.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,183,972 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 7,259 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 29,494 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 500,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:58 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 126,950 | $0.48 | $60,910.61 |
DisclosureSEC source: 0001415889-25-020245 · form4-07242025_080733.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,191,460 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 123,050 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 500,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 44,241 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 24, 2025 Filed May 28, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,488 | $0.47 | $3,544.07 |
DisclosureSEC source: 0001415889-25-014692 · form4-05282025_040502.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,318,410 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 7,259 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 44,241 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 750,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 20:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 126,950 | $0.78 | $98,551.29 |
DisclosureSEC source: 0001415889-25-011283 · form4-04242025_080425.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,325,898 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 123,050 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 750,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:30 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 1,750,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001415889-25-005704 · form4-02262025_100229.xml · derivative · entry 4 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750,000 Underlying: Common Stock · 1,750,000 shares Expires 2035-02-24 F7 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:30 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 375,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005704 · form4-02262025_100229.xml · nonDerivative · entry 3 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,452,848 F5 · shares: Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F6 · balance_after: Includes: (a) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:30 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 10,663 | $0.96 | $10,194.89 |
DisclosureSEC source: 0001415889-25-005704 · form4-02262025_100229.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,077,848 F3 · shares: Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F4 · balance_after: Includes: (a) 10,337 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 22:30 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,488 | $1.00 | $7,488.00 |
DisclosureSEC source: 0001415889-25-005704 · form4-02262025_100229.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,088,511 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 7,259 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 58,988 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 21,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final quarterly installment on February 25, 2025 and (c) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 412,584 | $1.15 | $474,471.60 |
DisclosureSEC source: 0001415889-25-002018 · form4-01242025_040101.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,095,999 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 587,416 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 1,000,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 21,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 73,735 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 10,642 | $1.94 | $20,645.48 |
DisclosureSEC source: 0001415889-24-027702 · form4-11262024_091121.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,508,583 F4 · shares: Represents shares underlying the portion of an RSU grant that vested on November 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 25, 2024 of $1.94/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 10,358 shares resulting from the November 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 21,000 shares will vest in one final installment on February 25, 2025, (b) 73,735 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| November 24, 2024 Filed Nov 26, 2024 21:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,473 | $1.88 | $14,049.24 |
DisclosureSEC source: 0001415889-24-027702 · form4-11262024_091121.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,519,225 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 22, 2024 of $1.88/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 7,274 shares resulting from the November 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 73,735 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 42,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 25, 2024 Filed Aug 27, 2024 20:36 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,492 | $0.86 | $6,443.12 |
DisclosureSEC source: 0001415889-24-022306 · form4-08272024_080830.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,526,698 F4 · shares: Represents shares underlying the portion of an RSU grant that vested on August 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 23, 2024 of $0.86/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 13,508 shares resulting from the August 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 42,000 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 88,482 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| August 24, 2024 Filed Aug 27, 2024 20:36 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 5,261 | $0.86 | $4,524.46 |
DisclosureSEC source: 0001415889-24-022306 · form4-08272024_080830.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,534,190 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 23, 2024 of $0.86/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 9,486 shares resulting from the August 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 88,482 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 63,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 25, 2024 Filed May 29, 2024 20:54 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,492 | $0.60 | $4,495.20 |
DisclosureSEC source: 0001415889-24-014775 · form4-05292024_080518.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,539,451 F4 · shares: Represents shares underlying the portions of RSU grants that vested on May 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 13,508 shares resulting from the from the May 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 63,000 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 103,229 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:54 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 5,261 | $0.60 | $3,156.60 |
DisclosureSEC source: 0001415889-24-014775 · form4-05292024_080518.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,546,943 F1 · shares: Represents shares underlying the portions of RSU grants that vested on May 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 9,485 shares resulting from the May 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 103,229 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 84,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2024 Filed Feb 27, 2024 22:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 24,157 | $1.13 | $27,297.41 |
DisclosureSEC source: 0001415889-24-005546 · form4-02272024_100241.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,552,204 F4 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 29,280 shares resulting from the February 25, 2024 final vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 13,697 shares resulting from the February 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 84,000 shares will vest in successive equal quarterly installments through February 25, 2025, (c) 117,975 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (d) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| February 24, 2024 Filed Feb 27, 2024 22:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 16,115 | $1.13 | $18,209.95 |
DisclosureSEC source: 0001415889-24-005546 · form4-02272024_100241.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,576,361 F1 · shares: Represents shares underlying the portions of RSU grants that vested on February 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 23,210 shares resulting from the February 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 117,975 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 105,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (d) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:39 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001754 · form4-01242024_090135.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,592,476 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration in full in the event of a Change in Control (as defined in the 2018 EIP). F2 · balance_after: Includes: (a) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (b) 105,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 157,300 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| November 25, 2023 Filed Nov 28, 2023 21:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 10,411 | $0.38 | $3,978.04 |
DisclosureSEC source: 0001209191-23-056786 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,476 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 10,589 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 105,000 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 157,300 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 20:13 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 10,411 | $0.77 | $8,016.47 |
DisclosureSEC source: 0001209191-23-047582 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,887 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 25, 2023 of $0.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 10,589 shares resulting from the August 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 126,000 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 157,300 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:40 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 10,411 | $1.33 | $13,846.63 |
DisclosureSEC source: 0001209191-23-032903 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,298 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 10,589 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 147,000 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 157,300 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2023 Filed Mar 6, 2023 22:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 54,767 | $2.66 | $145,680.22 |
DisclosureSEC source: 0001209191-23-016387 · doc4.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,709 F2 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: Includes: (a) 36,806 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 30,172 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 46,134 shares subject to such RSU grant that will vest in one final installment on February 25, 2024 and (c) 36,636 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 168,000 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 734,050 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-016387 · doc4.xml · derivative · entry 3 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,050 Underlying: Common Stock · 734,050 shares Expires 2033-02-23 F4 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 157,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016387 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,476 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 604,800 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014164 · doc4.xml · derivative · entry 3 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,800 Underlying: Common Stock · 604,800 shares Expires 2032-02-24 F4 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 224,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014164 · doc4.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,176 F3 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:16 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 49,890 | $5.90 | $294,351.00 |
DisclosureSEC source: 0001209191-22-014164 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,176 F1 · shares: Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 10,633 shares resulting from the February 25, 2022 final vesting installment of the Reporting Person's February 25, 2019 RSU grant, (b) 32,756 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 56,261 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023 and (c) 30,173 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 92,254 shares subject to such RSU grant that will vest in two remaining annual installments of 46,120 shares and 46,134 shares on February 25, 2023 and 2024, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 276,750 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015515 · doc4.xml · derivative · entry 3 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,750 Underlying: Common Stock · 276,750 shares Expires 2031-02-24 F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 138,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015515 · doc4.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,066 F3 · shares: Represents 138,375 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 35,311 | $11.19 | $395,130.09 |
DisclosureSEC source: 0001209191-21-015515 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,691 F1 · shares: Represents shares underlying the portions of restricted stock units ("RSUs") that vested on February 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2021 of $11.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 13,656 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2019 RSU grant and 21,087 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2022; and (b) 28,359 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2020 RSU grant and 112,505 shares subject to such RSU grant that will vest in two remaining annual installments of 56,244 shares and 56,261 shares on February 25, 2022 and 2023 respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| January 24, 2021 Filed Jan 27, 2021 01:24 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 3,977 | $14.95 | $59,456.15 |
DisclosureSEC source: 0001209191-21-005547 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,002 F1 · shares: Represents shares of common stock underlying the portion of the restricted stock unit ("RSU") grant surrendered by the Reporting Person to the Issuer for tax withholding upon settlement of such RSU grant on January 24, 2021, using the Issuer's closing stock price on January 22, 2021 of $14.95/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan. F2 · balance_after: Includes 6,523 shares common stock issued on January 24, 2021 upon settlement of Reporting Person's January 24, 2018 RSU grant. Additionally this amount includes: 42,168 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2019, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"); and F3 · balance_after: 168,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020 pursuant to the terms of the Issuer's Amended and Restated 2018 EIP, as amended. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:29 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 337,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-20-013228 · doc4.xml · derivative · entry 3 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,500 Underlying: Common Stock · 337,500 shares Expires 2030-02-24 F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:29 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 168,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013228 · doc4.xml · nonDerivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,979 F3 · shares: Represents 168,750 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:29 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,264 | $6.80 | $49,395.20 |
DisclosureSEC source: 0001209191-20-013228 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,229 F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on February 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2020 of $6.80/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes 13,818 shares resulting from the February 25, 2020 vesting of Reporting Person's February 25, 2019 restricted stock unit grant and 42,168 shares subject to such restricted stock unit grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 10,500 shares subject to restricted stock units granted on January 24, 2018 which reflects the final installment of such grant that will vest on January 24, 2021, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| January 24, 2020 Filed Jan 29, 2020 00:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 4,283 | $7.50 | $32,122.50 |
DisclosureSEC source: 0001209191-20-005247 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,493 F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on January 24, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on January 24, 2020 of $7.50/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan. F2 · balance_after: Includes 6,217 shares resulting from the January 24, 2020 vesting of Reporting Person's January 24, 2018 restricted stock unit grant and 10,500 shares subject to such restricted stock unit grant that will vest on January 24, 2021 resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Additionally, this amount includes 63,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 379,500 | $0.00 Strike: $9.03 | $0.00 |
DisclosureSEC source: 0001209191-19-014296 · doc4.xml · derivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,500 Underlying: Common Stock · 379,500 shares Expires 2029-02-24 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 63,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014296 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,776 F1 · balance_after: Represents 63,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Additionally, this amount includes 21,000 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| January 24, 2018 Filed Feb 1, 2018 01:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 189,000 | $0.00 Strike: $20.05 | $0.00 |
DisclosureSEC source: 0001209191-18-006340 · doc4.xml · derivative · entry 2 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,000 Underlying: Common Stock · 189,000 shares Expires 2028-01-23 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the January 24, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 24, 2018 Filed Feb 1, 2018 01:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-006340 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 F1 · balance_after: Represents 31,500 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| January 24, 2018 Filed Jan 28, 2019 22:45 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 3,974 | $11.10 | $44,111.40 |
DisclosureSEC source: 0001209191-19-005618 · doc4.xml · nonDerivative · entry 1 Macrae Sandy · CIK 0001675687 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,526 F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on January 24, 2019 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on January 24, 2019 of $11.10/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan. F2 · balance_after: Includes 6,526 shares resulting from the January 24, 2019 vesting of Reporting Person's January 24, 2018 restricted stock unit grant and 21,000 shares subject to such restricted stock unit grant that will vest in two (2) additional equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:56 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantEmployee Stock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001140361-17-003489 · doc1.xml · derivative · entry 1 Macrae Sandy · CIK 0001675687 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.